Literature DB >> 23639620

Factors associated with survival for patients with glioblastoma with poor pre-operative functional status.

Kaisorn L Chaichana1, Juan Carlos Martinez-Gutierrez, Rafael De la Garza-Ramos, Jon D Weingart, Alessandro Olivi, Gary L Gallia, Michael Lim, Henry Brem, Alfredo Quinones-Hinojosa.   

Abstract

Patients with glioblastoma (GB) are known to have poor prognoses, and among these patients, those with poor neurological function have an even poorer prognosis. Consequently, aggressive surgeries and adjuvant therapies are often withheld because of this dismal outlook. The effects of aggressive therapies in this small subset of patients remain unknown. The goal of this study was to evaluate outcomes and factors associated with survival for poor functioning patients who underwent aggressive resection of their GB. Adult patients who underwent surgical resection of an intracranial primary GB at an academic tertiary-care institution between 1997 and 2007 were retrospectively reviewed. Patients with a Karnofsky Performance Scale (KPS) score of ≤60 were included. A total of 100 patients with primary GB met the inclusion criteria. The average age (± standard deviation) and KPS score of this cohort were 54 ± 15 years and 53 ± 12, respectively. No patient (0%) experienced perioperative mortality, and 0 (0%), 10 (10%), and 3 (3%) of patients incurred a new or increasing language, motor, and visual deficit, respectively. At last follow-up, 88 (88%) patients died with a median survival of 6.6 months. The factors associated with improved survival were age <65 year (p = 0.005), tumor size >2 cm (p = 0.01), radical tumor resection (p=0.01), and temozolomide (p = 0.001). This study identifies a subset of patients with poor functional status who may benefit from aggressive surgical resection.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23639620      PMCID: PMC3994533          DOI: 10.1016/j.jocn.2012.07.016

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  27 in total

1.  Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study.

Authors:  B Jeremic; Y Shibamoto; D Grujicic; B Milicic; M Stojanovic; N Nikolic; A Dagovic; J Aleksandrovic
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  Karnofsky performance status revisited: reliability, validity, and guidelines.

Authors:  C C Schag; R L Heinrich; P A Ganz
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

3.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

4.  Accelerated fractionation radiotherapy for hospitalized glioblastoma multiforme patients with poor prognostic factors.

Authors:  J C Hernandez; Y Maruyama; R Yaes; H W Chin
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

5.  Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.

Authors:  Ovidiu Marina; John H Suh; Chandana A Reddy; Gene H Barnett; Michael A Vogelbaum; David M Peereboom; Glen H J Stevens; Heinrich Elinzano; Samuel T Chao
Journal:  J Neurosurg       Date:  2011-05-06       Impact factor: 5.115

6.  Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors.

Authors:  M Alonso; R Hamelin; M Kim; K Porwancher; T Sung; P Parhar; D C Miller; E W Newcomb
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors.

Authors:  Eric L Chang; Won Yi; Pamela K Allen; Victor A Levin; Raymond E Sawaya; Moshe H Maor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

8.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis.

Authors:  Kathleen R Lamborn; Susan M Chang; Michael D Prados
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

Review 9.  Factors influencing survival in high-grade gliomas.

Authors:  Jan C Buckner
Journal:  Semin Oncol       Date:  2003-12       Impact factor: 4.929

10.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.

Authors:  Edward R Laws; Ian F Parney; Wei Huang; Fred Anderson; Angel M Morris; Anthony Asher; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew Sloan; Mitchel S Berger; Susan Chang
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

View more
  13 in total

1.  Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study.

Authors:  E R Morgan; A Norman; K Laing; M D Seal
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

2.  Association between medical academic genealogy and publication outcome: impact of unconscious bias on scientific objectivity.

Authors:  Brian R Hirshman; Ali A Alattar; Sanjay Dhawan; Kathleen M Carley; Clark C Chen
Journal:  Acta Neurochir (Wien)       Date:  2019-01-23       Impact factor: 2.216

Review 3.  Treating glioblastoma patients with poor performance status: where do we go from here?

Authors:  Jaime Gállego Pérez-Larraya; François Ducray
Journal:  CNS Oncol       Date:  2014-05

4.  The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme.

Authors:  Lola B Chambless; Heather M Kistka; Scott L Parker; Laila Hassam-Malani; Matthew J McGirt; Reid C Thompson
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

5.  Clinical experience of glioma surgery using "tailed bullet": overcoming the limitations of conventional neuro-navigation guided surgery.

Authors:  Jin Mo Cho; Jae Joon Lim; Se-Hyuk Kim; Kyung Gi Cho
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

6.  Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.

Authors:  Riccardo Muglia; Matteo Simonelli; Federico Pessina; Emanuela Morenghi; Pierina Navarria; Pasquale Persico; Elena Lorenzi; Angelo Dipasquale; Marco Grimaldi; Marta Scorsetti; Armando Santoro; Letterio S Politi
Journal:  Eur Radiol       Date:  2020-11-17       Impact factor: 5.315

7.  Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.

Authors:  Sagar R Shah; Justin M David; Nathaniel D Tippens; Ahmed Mohyeldin; Juan C Martinez-Gutierrez; Sara Ganaha; Paula Schiapparelli; Duane H Hamilton; Claudia Palena; Andre Levchenko; Alfredo Quiñones-Hinojosa
Journal:  Cell Rep       Date:  2017-10-10       Impact factor: 9.423

8.  Incidental prostate-specific membrane antigen-avid glioblastoma detected on 68Ga-prostate-specific membrane antigen PET/CT.

Authors:  James Yuheng Jiang; Christine Kang; Paul Bui; Robert Mansberg
Journal:  Radiol Case Rep       Date:  2022-04-08

9.  A new functional classification system (FGA/B) with prognostic value for glioma patients.

Authors:  Katharina Friedlein; Yavor Bozhkov; Nirjhar Hore; Andreas Merkel; Björn Sommer; Sebastian Brandner; Michael Buchfelder; Nicolai E Savaskan; Ilker Y Eyüpoglu
Journal:  Sci Rep       Date:  2015-07-21       Impact factor: 4.379

10.  Predicting surgical outcome in patients with glioblastoma multiforme using pre-operative magnetic resonance imaging: development and preliminary validation of a grading system.

Authors:  Hani J Marcus; Sophie Williams; Archie Hughes-Hallett; Sophie J Camp; Dipankar Nandi; Lewis Thorne
Journal:  Neurosurg Rev       Date:  2017-02-15       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.